• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » RadPharm, Medifacts Merge into CoreLab Partners

RadPharm, Medifacts Merge into CoreLab Partners

February 16, 2010
CenterWatch Staff

Core laboratories RadPharm and Medifacts International recently merged business operations, hoping to attract new clients with their combined portfolios.

The deal, finalized Feb. 5, creates one company named CoreLab Partners (CoreLabs) with more than 400 employees (320 from RadPharm, 80 from Medifacts) and offices in New Jersey, Maryland, Germany and China. The new company’s main office is in Princeton, N.J.—RadPharm’s current headquarters.

Medifacts president Michael Woehler, Ph.D., is the new president and CEO of CoreLabs. Former RadPharm CEO Ronald Berg will become executive vice president, and all employees of each company will stay on with the CoreLabs.

“There is consolidation going on in the industry,” Woehler said. “We see that our clients—pharmaceutical companies, biotech companies, etc.—want to try to deal with less vendors, if you will. We thought this made sense. We can go into these clients, and we can talk about a very broad service offering now—kind of as one-stop shopping.”

Founded in 1985 as a contract research organization (CRO) and cardiovascular core lab, Medifacts filed for Chapter 11 bankruptcy protection in early 2007 before selling off the CRO division to focus on its cardiac safety services unit.

Medifacts’ survival post-bankruptcy was made possible by private-equity firms S.V. Sciences and Ampersand Ventures. Ampersand is RadPharm’s majority shareholder, Woehler said, so the companies knew each other well. 

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing